TetraKit

Next Generation Theranostics

circles design
molecules

TetraKit: Next Generation Theranostics

Targeted radionuclide therapy is an emerging field that has shown great promise in the treatment of late-stage metastatic cancer. Theranostics combines radionuclide therapy with diagnosis by nuclear imaging. In theranostics, cancer-targeting molecules, known as radiopharmaceuticals, carry radioactive atoms specifically to tumors. Depending on which type of radiation is chosen, physicians can either diagnose the severity and spread of the cancer or treat it by selectively destroying the cancerous tissue. TetraKit is a new, click chemistry based radiochemical platform, which allows for labeling of virtually any cancer-targeting molecule with any radionuclide pair for theranostics. TetraKit Technologies focuses its development program on fluorine-18 and astatine-211 as this pair is the best suited radionuclide pair for PET imaging and targeted alpha-radionuclide therapy. Alpha-therapy has attracted wide interest in current oncology as it succeeded where conventional therapies failed. TetraKit will develop the next generation of theranostic radiopharmaceuticals, which will improve patient care and disease outcomes.

Logo transparent

Latest news

from TetraKit Technologies

January 20, 2023

BioSeed 2023 in London

Our CEO, Andreas Jensen, will present at BioSeed in London, UK. Please reach us if you are interested in learning more about our universal labelling platform for theranostics and how it can be applied in your drug development programs. Schedule a meeting with Andreas Ingemann Jensen, PhD Pharm, by contacting him directly.
See you on Monday!

Read more

December 31, 2022

Happy New Year 2023 💫

As we start a new year, it is a time for reflection and setting new goals. The new year is a chance to leave the past behind and look toward the future with hope and determination. It is an opportunity to start fresh and make positive changes in our lives. I hope that this new year brings you joy, health, and prosperity and that you are able to achieve all that you set out to do. Happy New Year!

Read more

December 9, 2022

Ph.D. Fellowship

We are happy to announce a Ph.D. fellowship collaboration with Dept. of Drug Design and Pharmacology (ILF), University of Copenhagen. Welcome to apply via the Faculty of Health and Medical Sciences, https://healthsciences.ku.dk/
#university #collaboration #health #phd

Read more

Message from the CEO

Andreas Jensen, PhD

Andreas Jensen, PhD

Chief Executive Officer

Message from the CEO

“Targeted radionuclide therapy has been demonstrated to be very effective in oncology. However, a practical and universal labeling platform has thus far not been developed. TetraKit Technologies will develop such a platform. We expect that this platform will bring more powerful treatments to patients, especially with advanced metastatic cancer.”

Message from the CSO

Matthias Herth, PhD

Matthias Herth, PhD

Chief Scientific Officer

Message from the CSO

“TetraKit Technologies does not only provide a new platform enabling kit-labeling of almost any targeting vector with any radionuclide, but will also apply this technology to develop NextGen Theranostics based on the theranostic radionuclide pair fluoride-18 and astatine-211.”